HUP0203118A2 - Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0203118A2 HUP0203118A2 HU0203118A HUP0203118A HUP0203118A2 HU P0203118 A2 HUP0203118 A2 HU P0203118A2 HU 0203118 A HU0203118 A HU 0203118A HU P0203118 A HUP0203118 A HU P0203118A HU P0203118 A2 HUP0203118 A2 HU P0203118A2
- Authority
- HU
- Hungary
- Prior art keywords
- saturated
- optionally substituted
- unsaturated aliphatic
- heterocyclic group
- cycloaliphatic
- Prior art date
Links
- 239000003475 metalloproteinase inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
A találmány tárgyát általános képletű, metalloproteáz inhibitorvegyületek - ahol R1 hidroxi- vagy hidroxi-amino-csoport, R2 hidrogén-vagy halogénatom, adott esetben szubsztituált vagy heteroatommalmegszakított, telített vagy telítetlen alifás, ciklikus vagyheterociklusos csoport; R3 hidrogénatom, adott esetben szubsztituált,telített vagy telítetlen alifás vagy cikloalifás, aromás vagyheterociklusos csoport; R4 különböző összetett szubsztituensek; R5hidrogénatom, adott esetben szubsztituált, telített vagy telítetlenalifás vagy cikloalifás, aromás vagy heterociklusos csoport; R6 adottesetben szubsztituált, telített vagy telítetlen alifás vagycikloalifás, aromás vagy heterociklusos csoport vagy hidroxicsoportkülönböző fenntartásokkal; G oxigén- vagy kénatom, vagy G és Zegymástól függetlenül különböző kétértékű szubsztituensek - ésizomereik, diasztereomereik és enantiomereik, gyógyászatilagelfogadható sóik, biológiailag lebontható amidjaik, észtereik ésimidjeik, valamint ezeket tartalmazó gyógyszerkészítmények és ametalloproteázokkal kapcsolatos betegségek kezelésére valóalkalmazásuk képezik. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15932099P | 1999-10-14 | 1999-10-14 | |
PCT/US2000/028194 WO2001027084A1 (en) | 1999-10-14 | 2000-10-12 | Beta disubstituted metalloprotease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0203118A2 true HUP0203118A2 (hu) | 2003-01-28 |
HUP0203118A3 HUP0203118A3 (en) | 2003-05-28 |
Family
ID=22572063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203118A HUP0203118A3 (en) | 1999-10-14 | 2000-10-12 | Beta disubstituted metalloprotease inhibitors, pharmaceutical compositions containing them and their use |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1224171A1 (hu) |
JP (1) | JP2003519100A (hu) |
KR (1) | KR20020038951A (hu) |
CN (1) | CN1379762A (hu) |
AU (1) | AU8014500A (hu) |
BR (1) | BR0014759A (hu) |
CA (1) | CA2386485A1 (hu) |
CO (1) | CO5271694A1 (hu) |
CZ (1) | CZ20021161A3 (hu) |
HU (1) | HUP0203118A3 (hu) |
IL (1) | IL148893A0 (hu) |
MA (1) | MA25561A1 (hu) |
MX (1) | MXPA02003811A (hu) |
NO (1) | NO20021748L (hu) |
NZ (1) | NZ517983A (hu) |
PE (1) | PE20011003A1 (hu) |
PL (1) | PL355764A1 (hu) |
SK (1) | SK5082002A3 (hu) |
TR (1) | TR200200977T2 (hu) |
WO (1) | WO2001027084A1 (hu) |
ZA (1) | ZA200202207B (hu) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200305396A (en) * | 2002-03-27 | 2003-11-01 | Shionogi & Co | Cartilage extracellular matrix degradation |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
EP1689716A1 (en) | 2003-12-04 | 2006-08-16 | Wyeth | Biaryl sulfonamides and methods for using same |
JP2007524567A (ja) | 2003-12-04 | 2007-08-30 | ワイス | Mmp阻害剤としてのビアリールスルホンアミド |
US7576222B2 (en) | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
ATE462698T1 (de) * | 2005-06-29 | 2010-04-15 | Janssen Pharmaceutica Nv | Verfahren zur synthese von imidazolaminosäurederivaten und verwandten verbindungen |
CN107224675B (zh) * | 2016-03-25 | 2023-06-02 | 南京中硼联康医疗科技有限公司 | 硼中子捕获治疗*** |
WO2020206109A1 (en) * | 2019-04-02 | 2020-10-08 | The University Of Chicago | Remodilins for airway remodeling and organ fibrosis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998039313A1 (en) * | 1998-03-04 | 1998-09-11 | Monsanto Company | Thioaryl sulfonamide hydroxamic acid compounds |
EP0983267B1 (en) * | 1997-03-04 | 2005-01-26 | Pharmacia Corporation | Amidoaromatic ring sulfonamide hydroxamic acid compounds |
JP2001513484A (ja) * | 1997-07-31 | 2001-09-04 | ザ プロクター アンド ギャンブル カンパニー | 非環式メタロプロテアーゼ阻害剤 |
EP1054877A1 (en) * | 1998-02-11 | 2000-11-29 | Du Pont Pharmaceuticals Company | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors |
EP0967201A1 (en) * | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors |
BR0009244A (pt) * | 1999-03-03 | 2002-04-16 | Procter & Gamble | Inibidores de metaloprotease di-hétero substituìdos |
HUP0202199A2 (en) * | 1999-03-03 | 2002-10-28 | Procter & Gamble | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
-
2000
- 2000-10-12 HU HU0203118A patent/HUP0203118A3/hu unknown
- 2000-10-12 EP EP00970820A patent/EP1224171A1/en not_active Withdrawn
- 2000-10-12 WO PCT/US2000/028194 patent/WO2001027084A1/en not_active Application Discontinuation
- 2000-10-12 JP JP2001530105A patent/JP2003519100A/ja not_active Withdrawn
- 2000-10-12 IL IL14889300A patent/IL148893A0/xx unknown
- 2000-10-12 SK SK508-2002A patent/SK5082002A3/sk not_active Application Discontinuation
- 2000-10-12 AU AU80145/00A patent/AU8014500A/en not_active Abandoned
- 2000-10-12 TR TR2002/00977T patent/TR200200977T2/xx unknown
- 2000-10-12 MX MXPA02003811A patent/MXPA02003811A/es unknown
- 2000-10-12 BR BR0014759-1A patent/BR0014759A/pt not_active IP Right Cessation
- 2000-10-12 CN CN00814334A patent/CN1379762A/zh active Pending
- 2000-10-12 NZ NZ517983A patent/NZ517983A/en not_active Application Discontinuation
- 2000-10-12 CA CA002386485A patent/CA2386485A1/en not_active Abandoned
- 2000-10-12 CZ CZ20021161A patent/CZ20021161A3/cs unknown
- 2000-10-12 PL PL00355764A patent/PL355764A1/xx not_active Application Discontinuation
- 2000-10-12 KR KR1020027004754A patent/KR20020038951A/ko not_active Application Discontinuation
- 2000-10-13 PE PE2000001097A patent/PE20011003A1/es not_active Application Discontinuation
- 2000-10-13 CO CO00078367A patent/CO5271694A1/es not_active Application Discontinuation
-
2002
- 2002-01-01 ZA ZA200202207A patent/ZA200202207B/en unknown
- 2002-04-12 MA MA26597A patent/MA25561A1/fr unknown
- 2002-04-12 NO NO20021748A patent/NO20021748L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200202207B (en) | 2002-12-24 |
CN1379762A (zh) | 2002-11-13 |
SK5082002A3 (en) | 2002-10-08 |
CA2386485A1 (en) | 2001-04-19 |
BR0014759A (pt) | 2002-07-02 |
WO2001027084A1 (en) | 2001-04-19 |
IL148893A0 (en) | 2002-09-12 |
PE20011003A1 (es) | 2001-09-26 |
CZ20021161A3 (cs) | 2002-08-14 |
AU8014500A (en) | 2001-04-23 |
MXPA02003811A (es) | 2002-09-30 |
EP1224171A1 (en) | 2002-07-24 |
NO20021748L (no) | 2002-06-14 |
KR20020038951A (ko) | 2002-05-24 |
NZ517983A (en) | 2004-01-30 |
NO20021748D0 (no) | 2002-04-12 |
JP2003519100A (ja) | 2003-06-17 |
MA25561A1 (fr) | 2002-10-01 |
HUP0203118A3 (en) | 2003-05-28 |
PL355764A1 (en) | 2004-05-17 |
CO5271694A1 (es) | 2003-04-30 |
TR200200977T2 (tr) | 2002-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303084A2 (hu) | Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
MXPA03010435A (es) | Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes. | |
HUP0202381A2 (hu) | MEK-inhibitor hatású fenil-amino-benzoesav-származékok alkalmazása krónikus fájdalom kezelésére szolgáló gyógyszerkészítmények előállítására | |
TW429250B (en) | Novel heterocyclic derivatives and pharmaceutical use thereof | |
PA8463501A1 (es) | Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp) | |
ATE381537T1 (de) | Formanilid-derivative als beta2-adrenorezeptor- agonisten | |
NO20051265L (no) | Anvendelse av og noen nye imidazopyridiner | |
HUP0402376A2 (hu) | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
TR199800849T2 (xx) | Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri | |
DK0490772T3 (da) | 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem | |
HRP20040317A2 (en) | 1,8-naphthyridine derivatives as antidiabetics | |
NO945084L (no) | Substituerte heterocykliske karboksylsyreamider, deres fremstilling og anvendelse som legemiddel | |
JO2646B1 (en) | New differentiated cyclic compounds as beta - lactam inhibitors | |
ECSP034904A (es) | Derivados de índole naftil sustituido como inhibidores del activador plasminogen del inhibidor tipo-1 (pai-1) | |
NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
MY102866A (en) | Amide derivatives. | |
LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
DK0934309T3 (da) | Nye pyridylalkansyreamider som cytostatiske og immunosuppressive midler | |
AR002732A1 (es) | Derivados de 1,3-dihidro-1-(fenilalquilo)-2-h-imidazol-2-ona, uso de los derivados para preparar un medicamento, composiciones farmacéuticas que contienen dichos derivados, un procedimiento para su preparación, y un procedimiento para preparar dichos derivados | |
HUP0002272A2 (hu) | Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
ECSP045469A (es) | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas | |
NO911525L (no) | Nye 2,9-disubstituerte-4h-pyrido(1,2-a)pyrimidin-4-oner. | |
DK1295871T3 (da) | Vitamin D-derivater med et 22-oxa- eller 22-thiaatom, en C17-sidekæde substitueret med en syre-, ester- eller amid-gruppe og en 16(17)-dobbeltbinding | |
HUP0003577A2 (hu) | Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények |